Monoamine transporter gene structure and polymorphisms in relation to psychiatric and other complex disorders

被引：109

作者：

Hahn M.K. ^{[1
]}

Blakely R.D. ^{[1
]}

机构：

[1] Vanderbilt University, Department of Pharmacology, Center for Molecular Neuroscience, Nashville, TN 37232-6420

来源：

The Pharmacogenomics Journal | 2002年 / 2卷 / 4期

关键词：

Dopamine; Norepinephrine; Polymorphism; Serotonin; SNP; Transporter;

D O I：

10.1038/sj.tpj.6500106

中图分类号：

学科分类号：

摘要：

The norepinephrine, dopamine and serotonin transporters (NET, DAT and SERT, respectively), limit cellular signaling by recapturing released neurotransmitter, and serve as targets for antidepressants and drugs of abuse, emphasizing the integral role these molecules play in neurotransmission and pathology. This has compelled researchers to search for polymorphisms in monoamine (MA) transporter genes. Studies support linkage and association of MA transporter genetic variation in psychiatric and other complex disorders. Understanding the contribution of MA transporter polymorphisms to human behavior, disease susceptibility and response to pharmacotherapies will involve further progress in linkage and association that will be aided by both definition of highly selective phenotypes and utilization of a large number of polymorphic markers. The relationship of polymorphisms to alterations in transport capacity, likely a complex interaction, involving genetic background, disease state, and medication, will elucidate the means by which MA transporter genetic variability contributes to our individuality.

引用

页码：217 / 235

页数：18

共 155 条

[71]

Jacob G., Shannon J.R., Costa F., Furlan R., Biaggioni I., Mosqueda-Garcia R., Et al., Abnormal norepinephrine clearance and adrenergic receptor sensitivity in idiopathic orthostatic intolerance, Circulation, 99, pp. 1706-1712, (1999)

[72]

Eisenhofer G., Esler M.D., Meredith I.T., Dart A., Cannon R.O.D., Quyyumi A.A., Et al., Sympathetic nervous function in human heart as assessed by cardiac spillovers of dihydroxyphenylglycol and norepinephrine, Circulation, 85, pp. 1775-1785, (1992)

[73]

Shannon J.R., Flattem N.L., Jordan J., Jacob G., Black B.K., Biaggioni I., Et al., Clues to the origin of orthostatic intolerance: A genetic defect in the cocaine- and antidepressant sensitive norepinephrine transporter, New Engl. J. Med, 342, pp. 541-549, (2000)

[74]

Kilic F., Rudnick G., Oligomerization of serotonin transporter and its functional consequences, Proc. Natl. Acad. Sci. USA, 97, pp. 3106-3111, (2000)

[75]

Hastrup H., Karlin A., Javitch J.A., Symmetrical climer of the human dopamine transporter revealed by cross-linking Cys-306 at the extracellular end of the sixth transmembrane segment, Proc. Natl. Acad. Sci, 98, pp. 10055-10060, (2001)

[76]

Blakely R.D., Physiological genomics of antidepressant targets: Keeping the periphery in mind, J. Neurosci, 21, pp. 8319-8323, (2001)

[77]

Sano A., Kondoh K., Kakimoto Y., Kondo J., A 40-nucleoticle repeat polymorphism in the human dopamine transporter gene, Hum. Genet, 91, pp. 405-406, (1993)

[78]

Gelernter J., Kranzler H., Lacobelle J., Population studies of polymorphisms at loci of neuropsychiatric interest (tryptophan hydroxylase (TPH), dopamine transporter protein (SLC6A3), D3 cloparnine receptor (DRD3), apolipoprotein E (APOE), mu opioid receptor ciliary neurotrophic factor (CNTF)), Genomics, 52, pp. 289-297, (1998)

[79]

Kang A.M., Palmatier M.A., Kidd K.K., Global variation of a 40-bp VNTR in the 3′-untranslated region of the dopamine transporter gene (SLC6A3), Biol. Psychiatry, 46, pp. 151-160, (1999)

[80]

Mitchell R.J., Howlett S., Earl L., White N.G., McComb J., Schanfield M.S., Et al., Distribution of the 3′ VNTR polymorphism in the human dopamine transporter gene in world populations, Hum. Biol, 72, pp. 295-304, (2000)

← 3 4 5 6 7 8 9 10 11 12 →